Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Drug-Eluting Stent Restenosis: Modern Approach to a Classic Challenge

Author(s): Teodora Donisan*, Luai Madanat, Dinu V. Balanescu, Amy Mertens and Simon Dixon

Volume 19, Issue 3, 2023

Published on: 02 February, 2023

Article ID: e030123212355 Pages: 10

DOI: 10.2174/1573403X19666230103154638

Price: $65

Abstract

In-stent restenosis (ISR) is a recognized complication following percutaneous coronary intervention in which the luminal diameter is narrowed through neointimal hyperplasia and vessel remodeling. Although rates of ISR have decreased in most recent years owing to newer generation drug-eluting stents, thinner struts, and better intravascular imaging modalities, ISR remains a prevalent dilemma that proves to be challenging to manage. Several factors have been proposed to contribute to ISR formation, including mechanical stent characteristics, technical factors during the coronary intervention, and biological aspects of drug-eluting stents. Presentation of ISR can range from asymptomatic to late myocardial infarction and could be difficult to differentiate from acute thrombus formation. No definite guidelines are present on the management of ISR. In this review, we will discuss the mechanisms underlying ISR and provide insight into patient-related and procedural risk factors contributing to ISR, in addition to highlighting common treatment approaches utilized in the management of ISR.

Keywords: In-stent restenosis, drug-eluting stent, bare metal stent, DES-ISR, percutaneous coronary intervention, brachytherapy.

Graphical Abstract

[1]
Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103(24): 3019-41.
[http://dx.doi.org/10.1161/01.CIR.103.24.3019] [PMID: 11413094]
[2]
Farooq V, Gogas BD, Serruys PW. Restenosis. Circ Cardiovasc Interv 2011; 4(2): 195-205.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.110.959882] [PMID: 21505166]
[3]
Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331(8): 496-501.
[http://dx.doi.org/10.1056/NEJM199408253310802] [PMID: 8041414]
[4]
Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331(8): 489-95.
[http://dx.doi.org/10.1056/NEJM199408253310801] [PMID: 8041413]
[5]
Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773-80.
[http://dx.doi.org/10.1056/NEJMoa012843] [PMID: 12050336]
[6]
Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349(14): 1315-23.
[http://dx.doi.org/10.1056/NEJMoa035071] [PMID: 14523139]
[7]
Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356(10): 989-97.
[http://dx.doi.org/10.1056/NEJMoa066633] [PMID: 17296825]
[8]
Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375(9710): 201-9.
[http://dx.doi.org/10.1016/S0140-6736(09)62127-9] [PMID: 20060578]
[9]
Ahmed JM, Mintz GS, Waksman R, et al. Serial intravascular ultrasound assessment of the efficacy of intracoronary gamma-radiation therapy for preventing recurrence in very long, diffuse, in-stent restenosis lesions. Circulation 2001; 104(8): 856-9.
[http://dx.doi.org/10.1161/hc3301.095285] [PMID: 11514368]
[10]
Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369(9562): 667-78.
[http://dx.doi.org/10.1016/S0140-6736(07)60314-6] [PMID: 17321312]
[11]
Maehara A, Matsumura M, Ali ZA, Mintz GS, Stone GW. IVUS-guided versus OCT-guided coronary stent implantation. JACC Cardiovasc Imaging 2017; 10(12): 1487-503.
[http://dx.doi.org/10.1016/j.jcmg.2017.09.008] [PMID: 29216976]
[12]
Rittger H, Waliszewski M, Brachmann J, et al. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon versus Balloon Angioplasty. JACC Cardiovasc Interv 2015; 8(13): 1695-700.
[http://dx.doi.org/10.1016/j.jcin.2015.07.023] [PMID: 26476609]
[13]
Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis. J Am Coll Cardiol 2001; 38(3): 645-52.
[http://dx.doi.org/10.1016/S0735-1097(01)01431-0] [PMID: 11527611]
[14]
Turco MA, Ormiston JA, Popma JJ, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. JACC Cardiovasc Interv 2008; 1(6): 699-709.
[http://dx.doi.org/10.1016/j.jcin.2008.09.007] [PMID: 19463387]
[15]
Costa M, Angiolillo DJ, Teirstein P, et al. Sirolimus-eluting stents for treatment of complex bypass graft disease: Insights from the SECURE registry. J Invasive Cardiol 2005; 17(8): 396-8.
[PMID: 16079441]
[16]
Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362(9390): 1093-9.
[http://dx.doi.org/10.1016/S0140-6736(03)14462-5] [PMID: 14550694]
[17]
Groeneveld PW, Matta MA, Greenhut AP, Yang F. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol 2008; 51(21): 2017-24.
[http://dx.doi.org/10.1016/j.jacc.2008.01.057] [PMID: 18498954]
[18]
Garg S, Smith K, Torguson R, et al. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv 2007; 70(1): 9-14.
[http://dx.doi.org/10.1002/ccd.21106] [PMID: 17580367]
[19]
Lee SS, Price MJ, Wong GB, et al. Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. Am J Cardiol 2006; 98(10): 1345-8.
[http://dx.doi.org/10.1016/j.amjcard.2006.07.023] [PMID: 17134626]
[20]
Cosgrave J, Melzi G, Corbett S, et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent. Am Heart J 2007; 153(3): 354-9.
[http://dx.doi.org/10.1016/j.ahj.2006.12.009] [PMID: 17307411]
[21]
Moscarella E, Tanaka A, Ielasi A, et al. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVEISR Study). Catheter Cardiovasc Interv 2018; 92(4): 668-77.
[http://dx.doi.org/10.1002/ccd.27473] [PMID: 29356269]
[22]
Fan LM, Tong D, Mintz GS, Mamas MA, Javed A. Breaking the deadlock of calcified coronary artery lesions: A contemporary review. Catheter Cardiovasc Interv 2021; 97(1): 108-20.
[http://dx.doi.org/10.1002/ccd.29221] [PMID: 32865328]
[23]
Natalia M, Forero T, Daemen J. The Coronary Intravascular Lithotripsy System. Interv Cardiol 2019; 14(3): 174-81.
[http://dx.doi.org/10.15420/icr.2019.18.R1] [PMID: 31867065]
[24]
Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000; 101(18): 2165-71.
[http://dx.doi.org/10.1161/01.CIR.101.18.2165] [PMID: 10801757]
[25]
Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111(17): 2257-73.
[http://dx.doi.org/10.1161/01.CIR.0000163587.36485.A7] [PMID: 15867193]
[26]
Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17(3): 758-69.
[http://dx.doi.org/10.1016/S0735-1097(10)80196-2] [PMID: 1993798]
[27]
Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86(6) (Suppl.): III47-52.
[PMID: 1424051]
[28]
Vadasz B, Chen P, Yougbaré I, et al. Platelets and platelet alloantigens: Lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia. Genes Dis 2015; 2(2): 173-85.
[http://dx.doi.org/10.1016/j.gendis.2015.02.003] [PMID: 28345015]
[29]
Welt FGP, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22(11): 1769-76.
[http://dx.doi.org/10.1161/01.ATV.0000037100.44766.5B] [PMID: 12426203]
[30]
Schwartz RS, Topol EJ, Serruys PW, Sangiorgi G, Holmes DR Jr. Artery size, neointima, and remodeling: Time for some standards. J Am Coll Cardiol 1998; 32(7): 2087-94.
[PMID: 9857898]
[31]
Staab ME, Srivatsa SS, Lerman A, et al. Arterial remodeling after experimental percutaneous injury is highly dependent on adventitial injury and histopathology. Int J Cardiol 1997; 58(1): 31-40.
[http://dx.doi.org/10.1016/S0167-5273(96)02844-6] [PMID: 9021425]
[32]
Labinaz M, Pels K, Hoffert C, Aggarwal S, O’Brien ER. Time course and importance of neoadventitial formation in arterial remodeling following balloon angioplasty of porcine coronary arteries. Cardiovasc Res 1999; 41(1): 255-66.
[http://dx.doi.org/10.1016/S0008-6363(98)00203-X] [PMID: 10325973]
[33]
Di Mario C, Gil R, Camenzind E, et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol 1995; 75(12): 772-7.
[http://dx.doi.org/10.1016/S0002-9149(99)80409-3] [PMID: 7717277]
[34]
Dussaillant GR, Mintz GS, Pichard AD, et al. Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995; 26(3): 720-4.
[http://dx.doi.org/10.1016/0735-1097(95)00249-4] [PMID: 7642865]
[35]
Lee DH, Torre Hernandez JM. The Newest Generation of Drug-eluting Stents and Beyond. Eur Cardiol 2018; 13(1): 54-9.
[http://dx.doi.org/10.15420/ecr.2018:8:2] [PMID: 30310472]
[36]
Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56(23): 1897-907.
[http://dx.doi.org/10.1016/j.jacc.2010.07.028] [PMID: 21109112]
[37]
Yusuf R, Duan Z, Lamendola D, Penson R, Seiden M. Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3(1): 1-19.
[http://dx.doi.org/10.2174/1568009033333754] [PMID: 12570657]
[38]
Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001; 4(6): 378-91.
[http://dx.doi.org/10.1054/drup.2002.0227] [PMID: 12030785]
[39]
Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 2006; 95(8): 955-60.
[http://dx.doi.org/10.1038/sj.bjc.6603353] [PMID: 16953237]
[40]
Köster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000; 356(9245): 1895-7.
[http://dx.doi.org/10.1016/S0140-6736(00)03262-1] [PMID: 11130387]
[41]
Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47(1): 175-81.
[http://dx.doi.org/10.1016/j.jacc.2005.07.071] [PMID: 16386683]
[42]
Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001; 104(5): 600-5.
[http://dx.doi.org/10.1161/hc3101.092214] [PMID: 11479260]
[43]
Maluenda G, Ben-Dor I, Gaglia MA Jr, et al. Clinical outcomes and treatment after drug-eluting stent failure: The absence of traditional risk factors for in-stent restenosis. Circ Cardiovasc Interv 2012; 5(1): 12-9.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.111.963215] [PMID: 22319069]
[44]
Nomoto Y, Nakagawa M, Shirai N, et al. Neointimal coverage after second generation drug-eluting stent implantation has a relationship with pre-existing atherosclerotic lesion characteristics. Medicine (Baltimore) 2019; 98(37): e17097.
[http://dx.doi.org/10.1097/MD.0000000000017097] [PMID: 31517836]
[45]
Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J 2015; 36(32): 2147-59.
[http://dx.doi.org/10.1093/eurheartj/ehv205] [PMID: 25994755]
[46]
Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57(11): 1314-22.
[http://dx.doi.org/10.1016/j.jacc.2011.01.011] [PMID: 21376502]
[47]
Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52(5): 333-42.
[http://dx.doi.org/10.1016/j.jacc.2008.04.030] [PMID: 18652940]
[48]
Skålén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417(6890): 750-4.
[http://dx.doi.org/10.1038/nature00804] [PMID: 12066187]
[49]
Sano K, Mintz GS, Carlier SG, et al. Treatment of restenotic drug-eluting stents: An intravascular ultrasound analysis. J Invasive Cardiol 2007; 19(11): 464-8.
[PMID: 17986721]
[50]
Castagna MT, Mintz GS, Leiboff BO, et al. The contribution of “mechanical” problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J 2001; 142(6): 970-4.
[http://dx.doi.org/10.1067/mhj.2001.119613] [PMID: 11717599]
[51]
Wijns W, Shite J, Jones MR, et al. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. Eur Heart J 2015; 36(47): 3346-55.
[http://dx.doi.org/10.1093/eurheartj/ehv367] [PMID: 26242713]
[52]
de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998; 19(8): 1214-23.
[http://dx.doi.org/10.1053/euhj.1998.1012] [PMID: 9740343]
[53]
Zhang J, Gao X, Kan J, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation. J Am Coll Cardiol 2018; 72(24): 3126-37.
[http://dx.doi.org/10.1016/j.jacc.2018.09.013] [PMID: 30261237]
[54]
Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113(3): 414-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.563403] [PMID: 16432073]
[55]
Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115(18): 2426-34.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.658237] [PMID: 17485593]
[56]
Kuramitsu S, Iwabuchi M, Yokoi H, et al. Incidence and clinical impact of stent fracture after the Nobori biolimus-eluting stent implantation. J Am Heart Assoc 2014; 3(2): e000703.
[http://dx.doi.org/10.1161/JAHA.113.000703] [PMID: 24650925]
[57]
Kan J, Ge Z, Zhang JJ, et al. Incidence and Clinical Outcomes of Stent Fractures on the Basis of 6,555 Patients and 16,482 Drug-Eluting Stents From 4 Centers. JACC Cardiovasc Interv 2016; 9(11): 1115-23.
[http://dx.doi.org/10.1016/j.jcin.2016.02.025] [PMID: 27009464]
[58]
Shaikh F, Maddikunta R, Djelmami-Hani M, Solis J, Allaqaband S, Bajwa T. Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis? Catheter Cardiovasc Interv 2008; 71(5): 614-8.
[http://dx.doi.org/10.1002/ccd.21371] [PMID: 18360853]
[59]
Chinikar M, Sadeghipour P. Coronary stent fracture: a recently appreciated phenomenon with clinical relevance. Curr Cardiol Rev 2014; 10(4): 349-54.
[http://dx.doi.org/10.2174/1573403X10666140404105923] [PMID: 24720422]
[60]
Park KW, Park JJ, Chae IH, et al. Clinical characteristics of coronary drug-eluting stent fracture: Insights from a two-center des registry. J Korean Med Sci 2011; 26(1): 53-8.
[http://dx.doi.org/10.3346/jkms.2011.26.1.53] [PMID: 21218030]
[61]
Alexopoulos D, Xanthopoulou I. Coronary stent fracture: how frequent it is? Does it matter? Hellenic J Cardiol 2011; 52(1): 1-5.
[PMID: 21292601]
[62]
Sianos G, Hofma S, Ligthart JMR, et al. Stent fracture and restenosis in the drug-eluting stent era. Catheter Cardiovasc Interv 2004; 61(1): 111-6.
[http://dx.doi.org/10.1002/ccd.10709] [PMID: 14696169]
[63]
Adlakha S, Sheikh M, Wu J, et al. Stent fracture in the coronary and peripheral arteries. J Interv Cardiol 2010; 23(4): 411-9.
[http://dx.doi.org/10.1111/j.1540-8183.2010.00567.x] [PMID: 20806458]
[64]
Leong DP, Dundon BK, Puri R, Yeend RAS. Very late stent fracture associated with a sirolimus-eluting stent. Heart Lung Circ 2008; 17(5): 426-8.
[http://dx.doi.org/10.1016/j.hlc.2007.06.004] [PMID: 17728185]
[65]
Chung WS, Park CS, Seung KB, et al. The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Int J Cardiol 2008; 125(3): 325-31.
[http://dx.doi.org/10.1016/j.ijcard.2007.02.033] [PMID: 17434616]
[66]
Ishikawa K, Aoyama Y, Hirayama H. Management of drug-eluting stent restenosis. J Invasive Cardiol 2012; 24(4): 178-82.
[PMID: 22477755]
[67]
Balakrishnan B, Tzafriri AR, Seifert P, Groothuis A, Rogers C, Edelman ER. Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation 2005; 111(22): 2958-65.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.512475] [PMID: 15927969]
[68]
Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 2005; 111(13): 1619-26.
[http://dx.doi.org/10.1161/01.CIR.0000160363.30639.37] [PMID: 15795325]
[69]
Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: Molecular, cellular, and vascular behavior. J Am Coll Cardiol 2007; 49(25): 2379-93.
[http://dx.doi.org/10.1016/j.jacc.2007.02.059] [PMID: 17599600]
[70]
Wentzel JJ, Gijsen FJ, Schuurbiers JC, van der Steen AF, Serruys PW. The influence of shear stress on in-stent restenosis and thrombosis. EuroIntervention 2008; 4 (Suppl. C): C27-32.
[71]
Gijsen FJH, Oortman RM, Wentzel JJ, et al. Usefulness of shear stress pattern in predicting neointima distribution in sirolimus-eluting stents in coronary arteries. Am J Cardiol 2003; 92(11): 1325-8.
[http://dx.doi.org/10.1016/j.amjcard.2003.08.017] [PMID: 14636913]
[72]
Papafaklis MI, Chatzizisis YS, Naka KK, Giannoglou GD, Michalis LK. Drug-eluting stent restenosis: Effect of drug type, release kinetics, hemodynamics and coating strategy. Pharmacol Ther 2012; 134(1): 43-53.
[http://dx.doi.org/10.1016/j.pharmthera.2011.12.006] [PMID: 22212618]
[73]
Karanasiou GS, Papafaklis MI, Conway C, et al. Stents: Biomechanics, biomaterials, and insights from computational modeling. Ann Biomed Eng 2017; 45(4): 853-72.
[http://dx.doi.org/10.1007/s10439-017-1806-8] [PMID: 28160103]
[74]
Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282(21): 2035-42.
[http://dx.doi.org/10.1001/jama.282.21.2035] [PMID: 10591386]
[75]
Ueba H, Kawakami M, Yaginuma T. Shear stress as an inhibitor of vascular smooth muscle cell proliferation. Role of transforming growth factor-beta 1 and tissue-type plasminogen activator. Arterioscler Thromb Vasc Biol 1997; 17(8): 1512-6.
[http://dx.doi.org/10.1161/01.ATV.17.8.1512] [PMID: 9301628]
[76]
Papafaklis MI, Bourantas CV, Theodorakis PE, et al. The effect of shear stress on neointimal response following sirolimus- and paclitaxel-eluting stent implantation compared with bare-metal stents in humans. JACC Cardiovasc Interv 2010; 3(11): 1181-9.
[http://dx.doi.org/10.1016/j.jcin.2010.08.018] [PMID: 21087755]
[77]
Qin SY, Zhou Y, Jiang HX, Hu BL, Tao L, Xie M. The association of diabetes mellitus with clinical outcomes after coronary stenting: A meta-analysis. PLoS One 2013; 8(9): e72710.
[http://dx.doi.org/10.1371/journal.pone.0072710] [PMID: 24066025]
[78]
Zhao LP, Xu WT, Wang L, et al. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up. Coron Artery Dis 2015; 26(1): 5-10.
[http://dx.doi.org/10.1097/MCA.0000000000000170] [PMID: 25211654]
[79]
Yonetsu T, Kato K, Kim SJ, et al. Predictors for neoatherosclerosis. Circ Cardiovasc Imaging 2012; 5(5): 660-6.
[http://dx.doi.org/10.1161/CIRCIMAGING.112.976167] [PMID: 22798521]
[80]
Yan L, Xu MT, Yuan L, et al. Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China. J Clin Lipidol 2016; 10(1): 150-60.
[http://dx.doi.org/10.1016/j.jacl.2015.10.009] [PMID: 26892132]
[81]
Wang JL, Qin Z, Wang ZJ, et al. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J Geriatr Cardiol 2018; 15(2): 137-45.
[PMID: 29662507]
[82]
Barry A, Wilkinson I, Halford V, Springett K, McInnes A. A clinical study and the national service framework for diabetes. J Tissue Viability 2004; 14(4): 124.
[83]
Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014; 100(2): 153-9.
[http://dx.doi.org/10.1136/heartjnl-2013-304933] [PMID: 24270744]
[84]
Borges JC, Lopes N, Soares PR, et al. Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. J Cardiothorac Surg 2010; 5(1): 91.
[http://dx.doi.org/10.1186/1749-8090-5-91] [PMID: 20977758]
[85]
Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation 1989; 80(5): 1190-7.
[http://dx.doi.org/10.1161/01.CIR.80.5.1190] [PMID: 2680158]
[86]
Campbell PG, Teo KSL, Worthley SG, et al. Non-invasive assessment of saphenous vein graft patency in asymptomatic patients. Br J Radiol 2009; 82(976): 291-5.
[http://dx.doi.org/10.1259/bjr/19829466] [PMID: 19325046]
[87]
Scarsini R, Zivelonghi C, Pesarini G, Vassanelli C, Ribichini FL. Repeat revascularization: Percutaneous coronary intervention after coronary artery bypass graft surgery. Cardiovasc Revasc Med 2016; 17(4): 272-8.
[http://dx.doi.org/10.1016/j.carrev.2016.04.007] [PMID: 27215852]
[88]
Tejada JG, Velazquez M, Hernandez F, et al. Percutaneous revascularization in patients with previous coronary artery bypass graft surgery. Immediate and 1-year clinical outcomes. Int J Cardiol 2009; 134(2): 201-6.
[http://dx.doi.org/10.1016/j.ijcard.2008.01.042] [PMID: 18508141]
[89]
Sabik JF III, Blackstone EH, Gillinov AM, Smedira NG, Lytle BW. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation 2006; 114 (Suppl.): I454-60.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.001149] [PMID: 16820618]
[90]
Hwang MH, Meadows WR, Palac RT, et al. Progression of native coronary artery disease at 10 years: Insights from a randomized study of medical versus surgical therapy for angina. J Am Coll Cardiol 1990; 16(5): 1066-70.
[http://dx.doi.org/10.1016/0735-1097(90)90533-U] [PMID: 2229749]
[91]
Buch AN, Xue Z, Gevorkian N, et al. Comparison of outcomes between bare metal stents and drug-eluting stents for percutaneous revascularization of internal mammary grafts. Am J Cardiol 2006; 98(6): 722-4.
[http://dx.doi.org/10.1016/j.amjcard.2006.03.058] [PMID: 16950170]
[92]
Zavalloni D, Rossi ML, Scatturin M, et al. Drug-eluting stents for the percutaneous treatment of the anastomosis of the left internal mammary graft to left anterior descending artery. Coron Artery Dis 2007; 18(6): 495-500.
[http://dx.doi.org/10.1097/MCA.0b013e3282cf4ba9] [PMID: 17700223]
[93]
van der Heijden LC, Kok MM, Zocca P, et al. Long-term outcome of consecutive patients with previous coronary bypass surgery, treated with newer-generation drug-eluting stents. J Am Heart Assoc 2018; 7(3): e007212.
[http://dx.doi.org/10.1161/JAHA.117.007212] [PMID: 29382666]
[94]
Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia. J Am Coll Cardiol 2002; 40(11): 1951-4.
[http://dx.doi.org/10.1016/S0735-1097(02)02560-3] [PMID: 12475454]
[95]
Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials. Circulation 2002; 106(24): 3063-7.
[http://dx.doi.org/10.1161/01.CIR.0000041250.89627.A9] [PMID: 12473552]
[96]
Brilakis E, Saeed B, Banerjee S. Drug-eluting stents in saphenous vein graft interventions: A systematic review. EuroIntervention 2010; 5(6): 722-30.
[http://dx.doi.org/10.4244/EIJV5I6A119] [PMID: 20142225]
[97]
Aggarwal V, Stanislawski MA, Maddox TM, et al. Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions: Insights from the Veterans Affairs CART program. J Am Coll Cardiol 2014; 64(17): 1825-36.
[http://dx.doi.org/10.1016/j.jacc.2014.06.1207] [PMID: 25443706]
[98]
Kheiri B, Osman M, Abdalla A, Ahmed S, Bachuwa G, Hassan M. The short- and long-term outcomes of percutaneous intervention with drug-eluting stent vs. bare-metal stent in saphenous vein graft disease: An updated meta-analysis of all randomized clinical trials. Clin Cardiol 2018; 41(5): 685-92.
[http://dx.doi.org/10.1002/clc.22908] [PMID: 29749621]
[99]
Donisan T, Balanescu DV, Palaskas N, et al. Cardiac interventional procedures in cardio-oncology patients. Cardiol Clin 2019; 37(4): 469-86.
[http://dx.doi.org/10.1016/j.ccl.2019.07.012] [PMID: 31587788]
[100]
Sudasena D, Balanescu DV, Donisan T, et al. Fulminant vascular and cardiac toxicity associated with tyrosine kinase inhibitor sorafenib. Cardiovasc Toxicol 2019; 19(4): 382-7.
[http://dx.doi.org/10.1007/s12012-018-9499-2] [PMID: 30543051]
[101]
Balanescu DV, Donisan T, Dayah T, et al. Refractory radiation-induced coronary artery disease: Mapping the path and guiding treatment with optical coherence tomography. Int J Cardiovasc Imaging 2019; 35(5): 759-60.
[http://dx.doi.org/10.1007/s10554-019-01533-9] [PMID: 30758691]
[102]
Schömig K, Ndrepepa G, Mehilli J, Pache J, Kastrati A, Schömig A. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc Interv 2007; 70(3): 359-65.
[http://dx.doi.org/10.1002/ccd.21109] [PMID: 17722039]
[103]
Hess CN, Roe MT, Clare RM, et al. Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention. J Am Heart Assoc 2015; 4(7): e001779.
[http://dx.doi.org/10.1161/JAHA.115.001779] [PMID: 26150477]
[104]
Wang F, Gulati R, Lennon RJ, et al. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute st-segment elevation myocardial infarction. Mayo Clin Proc 2016; 91(12): 1680-92.
[http://dx.doi.org/10.1016/j.mayocp.2016.06.029] [PMID: 27916154]
[105]
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Thorac Cardiovasc Surg 2016; 152(5): 1243-75.
[http://dx.doi.org/10.1016/j.jtcvs.2016.07.044] [PMID: 27751237]
[106]
Balanescu DV, Aziz MK, Donisan T, et al. Cancer treatment resumption in patients with new-generation drug-eluting stents. Coron Artery Dis 2021; 32(4): 295-301.
[PMID: 33196581]
[107]
Potts JE, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: A report of the prevalence and outcomes in the United States. Eur Heart J 2019; 40(22): 1790-800.
[http://dx.doi.org/10.1093/eurheartj/ehy769] [PMID: 30500952]
[108]
Bossi I, Klersy C, Black AJ, et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35(6): 1569-76.
[http://dx.doi.org/10.1016/S0735-1097(00)00584-2] [PMID: 10807462]
[109]
Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151(6): 1260-4.
[http://dx.doi.org/10.1016/j.ahj.2005.08.011] [PMID: 16781233]
[110]
Lee MS, Pessegueiro A, Zimmer R, Jurewitz D, Tobis J. Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era. J Invasive Cardiol 2008; 20(8): 401-3.
[PMID: 18688064]
[111]
Nayak AK, Kawamura A, Nesto RW, et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J 2006; 70(8): 1026-9.
[http://dx.doi.org/10.1253/circj.70.1026] [PMID: 16864936]
[112]
Assali AR, Moustapha A, Sdringola S, et al. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). Am J Cardiol 2006; 98(6): 729-33.
[http://dx.doi.org/10.1016/j.amjcard.2006.04.007] [PMID: 16950172]
[113]
Steinberg DH, Pinto Slottow TL, Buch AN, et al. Impact of in-stent restenosis on death and myocardial infarction. Am J Cardiol 2007; 100(7): 1109-13.
[http://dx.doi.org/10.1016/j.amjcard.2007.05.033] [PMID: 17884372]
[114]
Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100(18): 1872-8.
[http://dx.doi.org/10.1161/01.CIR.100.18.1872] [PMID: 10545431]
[115]
Kim SW, Mintz GS, Escolar E, et al. An intravascular ultrasound analysis of the mechanisms of restenosis comparing drug-eluting stents with brachytherapy. Am J Cardiol 2006; 97(9): 1292-8.
[http://dx.doi.org/10.1016/j.amjcard.2005.11.055] [PMID: 16635598]
[116]
Bonello L, Kaneshige K, De Labriolle A, et al. Vascular brachytherapy for patients with drug-eluting stent restenosis. J Interv Cardiol 2008; 21(6): 528-34.
[http://dx.doi.org/10.1111/j.1540-8183.2008.00414.x] [PMID: 18973502]
[117]
Sethi A, Malhotra G, Singh S, Singh PP, Khosla S. Efficacy of various percutaneous interventions for in-stent restenosis: comprehensive network meta-analysis of randomized controlled trials. Circ Cardiovasc Interv 2015; 8(11): e002778.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.115.002778] [PMID: 26546577]
[118]
Alfonso F, Zueco J, Cequier A, et al. A randomized comparison ofrepeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003; 42(5): 796-805.
[http://dx.doi.org/10.1016/S0735-1097(03)00852-0] [PMID: 12957423]
[119]
Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D. Treatment strategies for coronary in-stent restenosis: Systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ 2015; 351: h5392.
[http://dx.doi.org/10.1136/bmj.h5392] [PMID: 26537292]
[120]
Adamian M, Colombo A, Briguori C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: A matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardiol 2001; 38(3): 672-9.
[http://dx.doi.org/10.1016/S0735-1097(01)01458-9] [PMID: 11527615]
[121]
Kobayashi Y, Teirstein PS, Linnemeier TJ, Stone GW, Leon MB, Moses JW. Rotational atherectomy (stentablation) in a lesion with stent underexpansion due to heavily calcified plaque. Catheter Cardiovasc Interv 2001; 52(2): 208-11.
[http://dx.doi.org/10.1002/1522-726X(200102)52:2<208:AID-CCD1049>3.0.CO;2-H] [PMID: 11170330]
[122]
Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents. Circ Cardiovasc Interv 2019; 12(8): e007023.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.118.007023] [PMID: 31345066]
[123]
Nikolakopoulos I, Vemmou E, Xenogiannis I, Brilakis ES. Combined use of intravascular lithotripsy and brachytherapy: A new approach for the treatment of recurrent coronary in-stent restenosis. Catheter Cardiovasc Interv 2021; 97(7): 1402-6.
[PMID: 33031640]
[124]
Russo F, Chieffo A, Carlino M, et al. Intravascular ultrasound-guided coronary lithotripsy treatment of in-stent restenosis in saphenous venous graft. J Invasive Cardiol 2021; 33(2): E141-2.
[PMID: 33531446]
[125]
Steinberg DH, Gaglia MA Jr, Pinto Slottow TL, et al. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol 2009; 103(4): 491-5.
[http://dx.doi.org/10.1016/j.amjcard.2008.09.107] [PMID: 19195508]
[126]
Kubo S, Kadota K, Otsuru S, et al. Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. EuroIntervention 2013; 9(7): 788-96.
[http://dx.doi.org/10.4244/EIJV9I7A131] [PMID: 24280155]
[127]
Torguson R, Sabate M, Deible R, et al. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. Am J Cardiol 2006; 98(10): 1340-4.
[http://dx.doi.org/10.1016/j.amjcard.2006.06.027] [PMID: 17134625]
[128]
Abouelnour A, Gori T. Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management. Front Cardiovasc Med 2022; 9: 843734.
[http://dx.doi.org/10.3389/fcvm.2022.843734] [PMID: 36017094]
[129]
Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2019; 55(1): 4-90.
[http://dx.doi.org/10.1093/ejcts/ezy289] [PMID: 30165632]
[130]
Giacoppo D, Alfonso F, Xu B, et al. Drug-Coated Balloon Angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol 2020; 75(21): 2664-78.
[http://dx.doi.org/10.1016/j.jacc.2020.04.006] [PMID: 32466881]

Rights & Permissions Print Cite
Article Metrics
41
2
© 2024 Bentham Science Publishers | Privacy Policy